ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO831

The Effect of Far Infrared Therapy on Peripheral Artery Disease in Hemodialysis Patients

Session Information

Category: Dialysis

  • 606 Dialysis: Epidemiology, Outcomes, Clinical Trials - Cardiovascular


  • Lin, Chih-Ching, Taipei Veterans General Hospital, Taipei City, Taiwan

In hemodialysis (HD) patients, peripheral artery disease (PAD) remains a critical cardiovascular complication which is usually diagnosed by ankle brachial index (ABI). Far infrared therapy improves access flow of vascular access but the effect on PAD in HD patients is still unknown.


We enrolled 198 maintenance HD patients in this study. PAD was defined as ABI ≤ 0.90. Only PAD patients received WS TY101 FIR emitter (Firapy) for 40 minutes during each HD session, three times weekly for six months. The ABI was measured for bilateral lower extremities for 4 times [pre-dialytic timing (0 minute) and 40 minutes after the initiation of HD session at both day 0 and 6 months after the FIR therapy].


Fifty-one out of 198 patients had PAD. In comparison with the period without FIR therapy in the 51 PAD patients, 6 months of FIR therapy significantly improved the ABI of right/ left side for 0 minute (from 0.77±0.19 to 0.81±0.20, P=0.027/0.79±0.20 to 0.81±0.17, P=0.049), 40 minutes during HD (from 0.73±0.23 to 0.83±0.19, P<0.001/ from 0.77±0.21 to 0.83±0.18, P<0.001) and incremental change between 0 and 40 minutes (from -0.04±0.14 to 0.02±0.13, P= 0.007/ from -0.02±0.13 to 0.02±0.14, P=0.012) respectively.


We demonstrate 40 minutes of FIR therapy three times weekly for 6 months improved ABI of both lower extremities, thus providing a new strategy for the treatment of PAD in HD patients.


  • Government Support - Non-U.S.